烯丙孕素
Altrenogest
17 alpha-Allyl-17beta-hydroxyestra-4,9,11-trien-3-one
別名: Regu-Mate · Matrix · allyl trenbolone · A-35957 · A-41300 · RH-2267 · RU-2267
由 VetSheet 獸醫團隊審訂更新於 2026年4月5日本內容以實證獸醫文獻為本
經審核的 v13 劑量證據
結構化劑量計算證據Suppression of estrus in normally cycling mares (extra-label)
須由已驗證獸醫確認
- q5-7d
NA
必須一併考量的臨床脈絡 (2)
- ■ Monitor pregnancy via ultrasonography and progesterone concentration 12
- ■ This medication is considered to be a hazardous drug as defined by the National Institute for Occupational Safety and Health (NIOSH). Talk with your veterinarian or pharmacist about the use of personal protective equipment when handling this medicine.
劑量為合格獸醫專業人員的臨床參考。請務必對照最新仿單及個別病患確認。
概覽
烯丙孕素（Altrenogest）是一種合成的口服孕激素，廣泛應用於獸醫繁殖醫學中。
- 馬：用於抑制母馬發情以利於週期同步化，並在黃體素不足或患有胎盤炎的母馬中維持妊娠。
- 豬：用於性成熟小母豬的發情同步化。
- 狗：標示外使用於黃體功能不全及作為安胎藥物以預防早產。
臨床提示：本藥物具高度脂溶性，極易穿透完整的人體皮膚吸收。對操作者（尤其是孕婦及有血栓或依賴雌激素疾病史的人）具有顯著的健康風險。
作用機轉
Altrenogest acts as an agonist at progesterone receptors.
- Transforms proliferative endometrium into secretory endometrium.
- Enhances myometrial hypertrophy and inhibits spontaneous uterine contractions (tocolytic effect).
- Exerts negative feedback on the hypothalamus and pituitary gland → inhibits secretion of GnRH → decreases release of pituitary gonadotropins (FSH and LH), thereby suppressing estrus and ovulation in a dose-dependent manner.
安全性與警告
禁忌症
- Horses intended for food purposes
- Mares with chronic uterine infections
- Manufacturer lists pregnancy as a contraindication (though clinically used extensively to maintain pregnancy)
不良反應
- Minimal at labeled dosages
- Slight, sporadic elevations in Ca++, K+, alkaline phosphatase, and AST
- May exacerbate chronic uterine infections
- Risk of pyometra in dogs (due to exogenous progesterone effects)
注意事項
Human Handling Warnings
Altrenogest can be absorbed through intact skin, and absorption is enhanced under occlusive materials (e.g., latex gloves). The following individuals MUST NOT handle this product:
- Women who are or suspect they are pregnant
- Anyone with a history of thrombophlebitis or thromboembolic disorders
- Anyone with cerebrovascular or coronary artery disease
- Women with known or suspected breast carcinoma
- People with known or suspected estrogen-dependent neoplasias
- Women with undiagnosed vaginal bleeding
- People with tumors that developed during the use of oral contraceptives
If skin exposure occurs, wash immediately with soap and water. If eye exposure occurs, flush with water for 15 minutes and seek medical attention.
藥物交互作用
May decrease progestin activity if administered concomitantly due to microsomal enzyme induction and increased progestin metabolism.
監測
- Pregnancy viability (via ultrasound)
- Endogenous progesterone levels (if treating luteal deficiency)
- Signs of pyometra in dogs
藥物動力學
半衰期
吸收
In horses, peak levels usually occur within 15-30 minutes post-dose (44 mg/kg PO).
排除
Primarily eliminated in the urine. Peak urine levels occur 3-6 hours after oral dosing. Detectable in urine up to 12 days post-administration.
過量
The LD50 of altrenogest is 175-177 mg/kg in rats. No specific information is available regarding the effects of an accidental acute overdose in horses or other veterinary species.
可用產品
劑型
- Oral solution: 0.22% (2.2 mg/mL) in oil
獸醫用
- Altrenogest 0.22% (2.2 mg/mL) in oil solution (Regu-Mate, Matrix)
各地核准狀態
暫無法規資料: 🇺🇸 US · 🇪🇺 EU · 🇬🇧 UK · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
儲存與穩定性
Store at room temperature. Altrenogest is extremely sensitive to light; dispense and store in light-resistant containers.
飼主須知
⚠️ 極度重要的操作警告
本藥物極易經由完整皮膚吸收，對特定人群具有嚴重的健康風險。
如果您屬於以下情況，請勿接觸本藥物：
- 懷孕或懷疑自己懷孕的女性
- 有血栓、中風或心臟病史的人
- 有乳腺癌或依賴雌激素腫瘤病史的人
- 有不明原因陰道出血的女性
操作指示：
- 接觸藥物或給藥器具時，請務必戴上無孔防護手套。
- 若藥物不慎接觸皮膚，請立即用肥皂和清水沖洗。
- 若不慎接觸眼睛，請用水沖洗15分鐘並就醫。
- 若不慎吞食，請勿催吐，應立即聯絡醫師或毒物控制中心。
寵物護理指示：
- 請嚴格按照獸醫的指示給藥。
- 請將藥物存放在避光處。
VetSheet 藥物參考供合格獸醫專業人員作臨床決策輔助之用，不能取代專業判斷或廠商最新仿單。